Markets

Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

Eli Lilly beats Q3 forecasts and lifts its 2026 sales target as demand for weight‑loss drug Zepbound and diabetes medicine Mounjaro surges.

◆2 independent outlets◆3 source items◆heat 0.28◆updated 8m

Outlets are counted by registrable domain, so a broadcaster’s station subdomains count once. 1 of the 3 items repeat an outlet already counted.

The engine’s read

Eli Lilly beats Q3 forecasts and lifts its 2026 sales target as demand for weight‑loss drug Zepbound and diabetes medicine Mounjaro surges.

Quarterly earnings surpass forecasts

Eli Lilly reported third‑quarter revenue and profit that exceeded analyst expectations. The company posted $5.35 billion in sales for Zepbound and $10.72 billion for Mounjaro, both above the estimates cited by StreetAccount. The new obesity pill Foundayo, launched in April, fell slightly short of Wall Street’s quarterly outlook.

Guidance raised on demand

Lilly lifted its full‑year 2026 revenue outlook to $91 billion‑$92 billion, up from the prior $85 billion‑$87 billion range. Adjusted earnings per share are now projected at $35‑$36, compared with the earlier $35.50‑$36.50 range. The company said the stronger outlook reflects resilient demand for Zepbound and Mounjaro, despite lower U.S. net prices.

Additional business moves

In the same release, Lilly highlighted expanded Medicare coverage for GLP‑1 obesity drugs under a temporary pilot program. It also disclosed a deal to acquire Merida Biosciences, aiming to develop new treatments for serious autoimmune and allergic diseases.

Coverage

2 independent outlets filed 3 reports over 2 hours.

2outlets
3filings
2hspan
singletrend
What could happen next
No outcome sealed yet.the engine has not sealed a forecast on this story yet. The forecast is always written to the ledger before any article about it, never the other way round.
The evidence3 items
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Campari sales beat estimates but stock slips 5% on US outlook
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Sources are evidence, not content. Each keeps its own name, its own link and an extract capped at 400 characters; none of it is rewritten into the copy above.

More from Markets
1/8All →